In kidney transplantation, ongoing alloimmune processes—commonly triggered by HLA
incompatibilities—can trigger chronic transplant rejection, affecting the microcirculation and …

Kidney transplant patients require careful management of immunosuppression to avoid
rejection while minimizing the risk of infection and malignancy for the best long-term …

Background: Conversion to a belatacept-based immunosuppression is currently used as a
calcineurin inhibitors (CNI) avoidance strategy when the CNI-based standard of care …

Natural killer (NK) cells respond to diseased and allogeneic cells through NKG2A/HLA-E or
killer cell immunoglobulin-like receptor (KIR)/HLA-ABC interactions. Correlations between …

People with Parkinson's disease (PD) are prescribed a variety of medications to mitigate
symptoms and improve their quality of life. These symptomatic therapies cover a range of …

Biopsy-proven acute rejection (BPAR) occurs in approximately 10% of kidney transplant
recipients in the first year, making superiority trials unfeasible. iBOX, a quantitative …

Further improvements of outcome after solid organ transplantation will depend on our ability
to integrate personalized medicine in clinical routine. Not only better risk stratification or …

The transplant community suffers from a serious drought; the pipeline for new
immunosuppressants has been empty since the approval of belatacept in 2011. 1, 2 There …

Background: Prognostic models are becoming increasingly relevant in clinical trials as
potential surrogate endpoints, and for patient management as clinical decision support tools …

Background Prognostic models are becoming increasingly relevant in clinical trials as
potential surrogate endpoints, and for patient management as clinical decision support tools …